Imatinib Inteli (Imatinib)

Imatinib blocks the ATP‑binding pocket of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases. By preventing phosphorylation of downstream signaling proteins, it stops the proliferative and anti‑apoptotic signals that cancer cells rely on, leading to reduced tumor growth and increased cell death.

The specific dose of Imatinib Inteli is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal and hepatic function, and other individual factors. Healthcare professionals set the regimen according to approved labeling and clinical guidelines.

Safety data for Imatinib in pregnancy and lactation are limited. The drug is generally avoided unless the potential benefit to the mother outweighs possible risks to the fetus or infant. Women of childbearing potential should use effective contraception and discuss any plans for pregnancy with their physician.

To request Imatinib Inteli, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and required import documentation.

Imatinib was the first BCR‑ABL tyrosine‑kinase inhibitor approved for CML and remains a standard first‑line option. Newer agents such as dasatinib and nilotinib have higher potency and may be used in cases of resistance or intolerance, but Imatinib offers a well‑characterized safety profile and extensive long‑term data.

Imatinib Inteli should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and excessive heat to maintain potency throughout its shelf life.

Imatinib Inteli is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and not alter the regimen without medical advice.

Serious adverse events include severe neutropenia, hepatotoxicity, cardiac dysfunction, pulmonary hypertension, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for laboratory abnormalities and clinical signs of these conditions.

Imatinib Inteli is contraindicated in patients with known hypersensitivity to imatinib or any of its excipients. Caution is also advised for individuals with uncontrolled cardiac disease, severe hepatic impairment, or those receiving strong CYP3A4 inducers that could markedly reduce drug exposure.